Spots Global Cancer Trial Database for HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Official Title: A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Study ID: NCT02947152
Interventions
Study Description
Brief Summary: A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Nagoya, Aichi, Japan
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Locarno, , Switzerland
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
